EMA Withdrawn: Beqvez (previously Durveqtix) (fidanacogene elaparvovec) — Pfizer Europe MA EEIG

View source ↗

Summary

EMA has withdrawn Beqvez (fidanacogene elaparvovec) for Hemophilia B. The product was previously named Durveqtix and had conditional approval before the withdra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Beqvez (fidanacogene elaparvovec)
• Durveqtix

Snippet

Status: Withdrawn. Therapeutic area: Hemophilia B. MAH: Pfizer Europe MA EEIG. Decision date: 24/09/2024. Conditional approval